GlycoEra Appoints Petra Duda as Chief Medical Officer to Lead Precision Protein Degrader Pipeline
核心洞察
GlycoEra AG (搜索) has appointed Petra Duda, M.D., Ph.D., as Chief Medical Officer to lead clinical development of its precision immune degrader pipeline.
Dr. Duda brings over 20 years of experience in clinical development and regulatory strategy, with expertise in immune-mediated and rare diseases.
She will oversee advancement of GlycoEra's lead IgG4 (搜索) degrader program GE8820 for autoimmune diseases (搜索) including pemphigus (搜索), MuSK MG (搜索), and primary membranous nephropathy (搜索).
GlycoEra AG (搜索) announced the appointment of Petra Duda, M.D., Ph.D., as Chief Medical Officer to lead clinical development and medical strategy for the biotechnology company's precision immune degrader pipeline. Dr. Duda brings more than 20 years of global leadership experience in clinical development, medical affairs, and regulatory strategy, with deep expertise in immune-mediated and rare diseases.
The appointment positions GlycoEra to advance its lead IgG4 (搜索) degrader program, GE8820, across multiple autoimmune diseases (搜索) including pemphigus (搜索), MuSK myasthenia gravis, and primary membranous nephropathy (搜索). The company is pioneering extracellular protein degraders using glyco-engineering technology to precisely target and degrade circulating, disease-causing proteins.
Leadership Transition and Strategic Vision
"Petra is an exceptional clinical leader with a proven track record translating novel biology into impactful therapies for patients," said Ganesh Kaundinya, Ph.D., Chief Executive Officer of GlycoEra. "Her experience driving global approvals in complex immune disorders and rare diseases, combined with her strategic insight, will be instrumental as we advance GE8820 and expand our portfolio of degraders that have the potential to redefine treatment paradigms in multiple diseases."
Dr. Duda expressed enthusiasm about joining the company at this pivotal stage of development. "The company's unique glyco-engineering platform is enabling a fundamentally differentiated approach to degrading disease-causing proteins," she said. "These therapies have the potential to rewrite how patients are treated in immunology, delivering earlier and more durable responses, no generalized immunosuppression and potential for superior efficacy."
Extensive Clinical Development Experience
Dr. Duda's career spans multiple leadership roles across biotechnology and pharmaceutical companies. Most recently, she served as Chief Medical Officer at Inozyme Pharma in Boston, where she oversaw a clinical portfolio focused on rare and ultra-rare diseases and guided programs through key developmental stages.
Prior to Inozyme, Dr. Duda served as Global Development Lead at UCB (搜索), where she oversaw the Zilbrysq® (zilucoplan) program and led it through global regulatory approvals for the treatment of generalized myasthenia gravis (搜索). She joined UCB through its acquisition of Ra Pharmaceuticals, where she directed the development of complement pathway (搜索) inhibitors.
Earlier in her career, Dr. Duda held senior clinical roles at Sarepta Therapeutics, where she contributed to the development and approval of Exondys 51® for Duchenne muscular dystrophy (搜索), and at Biogen Idec, where she led neurology development programs. She also held positions in medical affairs and drug safety at Boehringer Ingelberg.
Academic and Professional Credentials
Dr. Duda is board certified in Neurology and Pharmaceutical Medicine. She earned her M.D. and Ph.D. in molecular biology and biochemistry from the University of Bern, providing her with both clinical expertise and deep scientific understanding of the molecular mechanisms underlying disease.
GlycoEra's Platform and Pipeline
GlycoEra AG (搜索) is dedicated to developing protein degraders to transform the treatment of autoimmune diseases (搜索). The company harnesses glycoengineering to precisely target and degrade circulating, disease-causing proteins, advancing a differentiated platform and pipeline of therapies targeting autoimmune and inflammatory diseases.
The company is headquartered in Waedenswil, Zurich, Switzerland with additional offices and laboratories in Newton, Massachusetts. Under Dr. Duda's leadership, GlycoEra aims to bring its innovative protein degrader therapies into clinical development and ultimately to patients who need new treatment options.